Clinical trial
A Phase 1b Study to Characterise the Pharmacokinetic/Pharmacodynamic Relationship of Pyronaridine in Healthy Adult Participants Experimentally Infected With Blood Stage Plasmodium Falciparum.
NCT05287893 is registered in ClinicalTrials.gov with Medicines for Malaria Venture as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b Study to Characterise the Pharmacokinetic/Pharmacodynamic Relationship of Pyronaridine in Healthy Adult Participants Experimentally Infected With Blood Stage Plasmodium Falciparum.
- Lead sponsor
- Medicines for Malaria Venture
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- April 4, 2022
- Completion date
- September 26, 2022
- Enrollment
- 10 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
malaria, malaria recrudescence, malaria,falciparum, parasitemia, parasitic disease, protozoan infections